LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News:

?The research and development that VALBIOTIS is doing is very promising. We look forward to working together to realize the commercialization of TOTUM-63, an innovative approach to reducing the risk of Type 2 Diabetes.?

Tweet this

VALBIOTIS (Paris:ALVAL) (FR0013254851 ? ALVAL / PEA/SME eligible ), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the signature of a global long-term strategic partnership with Nestl? Health Science for the development and commercialization of TOTUM-63, an innovative and patented combination of 5 plant extracts specifically designed to reduce the risk of developing Type 2 Diabetes on prediabetics. S?bastien PELTIER, CEO of VALBIOTIS?states: ?Nestl? Health Science is an ideal strategic partner for VALBIOTIS. Its global reach, strategic intent to develop science-based nutritional health solutions and focus on fighting metabolic disorders like diabetes will be instrumental to TOTUM-63's worldwide commercialization success. We are excited about the opportunity that this deal brings to VALBIOTIS and to the many millions of people around the world at risk of becoming Type 2 diabetics. This transformational deal arrives just five years after the creation of VALBIOTIS and is a recognition of the hard work, commitment and vision of our team?. Hans-Juergen WOERLE, Chief Science & Medical Officer of Nestl? Health Science, said,?"The research and development that VALBIOTIS is doing is very promising. We look forward to working together to realize the commercialization of TOTUM-63, an innovative approach to reducing the risk of Type 2 Diabetes." Under the terms of the agreement, VALBIOTIS grants Nestl? Health Science exclusive and global commercial rights to use TOTUM-63 in the prediabetes and Type 2 Diabetes market. The agreement defines a number of priority markets for a global commercialization. In exchange for these rights, Nestl? Health Science commits to an upfront payment of CHF 5 million, development & sales milestone payments up to a maximum of CHF 66 million, and tiered royalties on net sales. The partnership will support VALBIOTIS's work in a number of ways, including funding the latest clinical development phase until health claims are obtained by the appropriate authorities in the United States and Europe. The financial terms of this agreement significantly extend VALBIOTIS?s cash runway. The commercialization of TOTUM-63 may take place before obtaining health claims. Agreement also includes TOTUM-63 supply to Nestl? Health Science, representing an additional source of revenue for VALBIOTIS. As part of the agreement, a joint steering committee comprised of representatives of both companies will oversee clinical development, regulatory matters, supply and commercialization. Beyond this strategic partnership on TOTUM-63 to reduce the risk of developing Type 2 Diabetes, VALBIOTIS intends to pursue its other R&D programs: TOTUM-070, to reduce blood LDL-cholesterol, an independent risk factor for cardiovascular diseases, TOTUM-854¹, to reduce blood pressure, an independent risk factor for cardiovascular diseases and TOTUM-448¹, in fatty liver disease, a condition with high risk of developing NASH. The Company will provide further details on its pipeline in a subsequent communications. Resumption of trading of VALBIOTIS shares on Euronext Growth will take place on February 6, 2020 at 9:00 am. ABOUT TOTUM-63 TOTUM-63 is a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of Type 2 Diabetes. TOTUM-63 has already been proven safe and effective in healthy human volunteers during a Phase I/II clinical study. The results of the international randomized, placebo-controlled Phase II study showed that TOTUM-63 reduced fasting and 2-hour blood sugar levels, two risk factors for Type 2 Diabetes, in prediabetics compared to placebo. In these subjects, who also had abdominal obesity, TOTUM-63 significantly reduced body weight and waist circumference. TOTUM-63 benefits from intellectual property granted in the main markets worldwide: Europe (covering 39 countries), the United States, Russia and national phases are underway in more than 20 countries including China, Japan, Brazil, Australia. The ability to produce TOTUM-63 industrially, in compliance to North American and European standards, has been validated. TOTUM-63 already has marketing authorizations related to its status in Europe. ABOUT NESTLE HEALTH SCIENCE Nestl? Health Science (NHSc), a wholly-owned subsidiary of Nestl?, is a globally recognized leader in the field of nutritional science. At NHSc we are committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. We offer an extensive consumer health portfolio of industry-leading medical nutrition, consumer and VMS brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. Headquartered in Switzerland, NHSc employs over 5?000 people around the world, who are committed to making a difference in people?s lives, for a healthier today and tomorrow. For more information, please visit:?www.nestlehealthscience.com. ABOUT VALBIOTIS VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs. VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients. Its products are intended to be licensed to players in the health world. VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France ? P?rigny, La Rochelle (17) and Riom (63). VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company. For more information about VALBIOTIS, please visit:?www.valbiotis.com

Name: Valbiotis ISIN code: FR0013254851 Mnemonic code: ALVAL

Disclaimer This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 31 July 2019 (application number R19-030) as well in its supplement approved by the AMF on Octobre 9, 2019. These documents being available on the Company?s website (www.valbiotis.com). This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country. 1. TOTUM-854 and TOTUM-448 are active substances from the VAL-63 research program. They are ready to enter Phase II clinical development.